Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
October 30, 2023 09:15 ET
|
Aptose Biosciences, Inc.
Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients
Interchangeable Biosimilars Market revenue to hit USD 65 Billion by 2035, says Research Nester
September 11, 2023 07:00 ET
|
Research Nester
New York, Sept. 11, 2023 (GLOBE NEWSWIRE) -- The global Interchangeable Biosimilars market size is slated to expand at ~ 20 % CAGR between 2023 and 2035. The market is poised to garner a revenue of...
Companion Animal Diagnostics Market Predicted to Reach USD 1591 million by 2027, Expanding at a CAGR of 10% - Exclusive Report by Transparency Market Research
September 04, 2023 06:27 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Sept. 04, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global companion animal diagnostics market is projected to flourish at a CAGR of 10%...
Global CAR T-Cell Therapy Market Size on a Meteoric Rise: Envisioning $2406.39 Million by 2030 with a Striking CAGR of 26.20%
August 23, 2023 04:51 ET
|
Zion Market Research
New York, NY, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “CAR T-Cell Therapy Market By Drug Type (Axicabtagene Ciloleucel, Brexucabtagene...
Pluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation
August 16, 2023 07:00 ET
|
Pluri Inc.
Results support the development of PLX-R18 for hematologic acute radiation syndrome (H-ARS), currently under a $4.2 million contract with the U.S. National Institutes of HealthPLX-R18 has the...
Aptose Reports Results for the Second Quarter 2023
August 10, 2023 16:02 ET
|
Aptose Biosciences, Inc.
─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc 43% in Patients with Wildtype FLT3 ── CRc 67%...
Plasma Fractionation Market revenue to exceed USD 37 Billion by 2033, says Research Nester
July 31, 2023 06:00 ET
|
Research Nester
New York, July 31, 2023 (GLOBE NEWSWIRE) -- The global plasma fractionation market size is slated to expand at ~7% CAGR between 2023 and 2033. The market is poised to garner a revenue of USD 37...
Targeted Oncology™ announces recipients of its Q2 Oncology Icons award program
July 18, 2023 10:44 ET
|
Targeted Oncology™
CRANBURY, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Targeted Oncology, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of...
$2.68Bn Growth for Companion Animal Diagnostics Market to Hit 4.1% CAGR, Globally, by 2027 with Clinical Biochemistry Segment Driving Growth during 2020-2027 | The Insight Partners
July 11, 2023 09:26 ET
|
The Insight Partners
Pune, India, July 11, 2023 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Companion Animal Diagnostics Market Size Report, Share, Revenue, Growth Strategy, Industry...
BTG Pharmaceuticals Statement on NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Use of Glucarpidase (Voraxaze®) and MTXPK.org
June 22, 2023 08:28 ET
|
BTG Specialty Pharmaceuticals
West Conshohocken, PA, June 22, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, highlights the recent updates to the National Comprehensive Cancer Network (NCCN) Guidelines for Acute...